Catheter Related Bloodstream Infections Market Outlook - Forecast Trends, Market Size, Share and Growth Analysis Report (2025-2034)

The catheter related bloodstream infections market was valued at USD 1.26 billion in 2024, driven by the rising hospital admissions and advancements in catheter technology across the 8 major markets. The market is expected to grow at a CAGR of 4.99% during the forecast period of 2025-2034, with the values likely to reach USD 2.06 billion by 2034 .

Catheter Related Bloodstream Infections Market Overview

Catheter-related bloodstream infections (CRBSI) are primarily caused by the placement of a central venous catheter or arterial line. It is a major factor resulting in hospital-acquired infection and is associated with significant mortality, morbidity, and healthcare costs. The bloodstream infection by a catheter is typically caused by coagulase-negative staphylococci, enterococci, and Candida species, among others. The heightened awareness about the risks of catheter use and the importance of infection control measures is influencing the market landscape for catheter related bloodstream infections. Further, the rising hospital admissions and the growing aging population are major drivers of the market growth. Other factors such as the implementation of strict infection control protocols, advancements in catheter technology, and increased efforts to upgrade the healthcare infrastructure are poised to support market expansion.

Catheter Related Bloodstream Infections Market Growth Drivers

Stringent Regulatory Guidelines on Bloodstream Infection Control to Affect the Market Landscape Significantly

In May 2024, the first global guidelines, aimed at preventing bloodstream infections and others caused as a result of catheter placement in minor blood vessels, was published by the World Health Organization (WHO). These new guidelines comprised 14 good practice statements along with 23 recommendations on major areas for healthcare professionals, including catheter selection, insertion, maintenance, and removal. The implementation of such recommendations is anticipated to encourage healthcare facilities to adopt advanced solutions for infection prevention and control, thereby boosting market growth.

Technological Advancements to Boost Catheter Related Bloodstream Infections Market Demand

In December 2023, the researchers at Texas A&M University (College Station, Texas, United States) reported the development of an innovative catheter dressing that can reduce the severity and frequency of catheter related bloodstream infections. This dressing leverages wireless sensors that can automatically and swiftly detect extremely low levels of bacterial growth on the skin. Such technological advancements are likely to lead to immediate and targeted antibiotic treatments and are expected to fuel market growth in the forecast period.

Catheter Related Bloodstream Infections Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rising Hospital Admissions

The market is witnessing an increased number of hospital admissions, particularly in intensive care units (ICUs). This is resulting in a growing use of central venous catheters, which are associated with a higher risk of bloodstream infections. Thus, the rising hospital admissions augment the demand for effective prevention and treatment solutions.

Adoption of Antimicrobial-Coated Catheters

One of the major market trends is the growing adoption of catheters coated with antimicrobial agents such as silver, chlorhexidine, and other antiseptics to prevent infection. Such coating on catheters helps in reducing microbial growth on its surface and thereby lowers the risk of infection.

Investments in R&D

The catheter related bloodstream infections market value is impacted by the rising investment in research and development focused on introducing new antimicrobial agents, better catheter materials, and advanced diagnostic tools. Such investment that aims at accelerating the development of new solutions for CRBSI prevention and management is anticipated to boost market growth.

Increased Focus on Training Healthcare Professionals

The market is benefitting from the growing emphasis on training healthcare professionals. Such training programs ensure that the professionals are following best practices for catheter insertion and maintenance and are expected to elevate the market value in the forecast period.

Catheter Related Bloodstream Infections Market Segmentation

The EMR’s report titled “Catheter Related Bloodstream Infections Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class

• Antibiotics
• Cloxacillin
• Ceftazidime
• Cefazoline
• Daptomycin
• Vancomycin
• Teicoplanin
• Echinocandin
• Non-Antibiotics

Market Breakup by Route of Administration

• Oral
• Injectables

Market Breakup by Indication

• Bacterial Infections
• Fungal Infection
• Viral and Parasitic Infections

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Japan
• India

Catheter Related Bloodstream Infections Market Share

Market Segmentation Based on Drug Class is Poised to Experience Substantial Growth

The market can be segmented by drug class into non-antibiotics, and antibiotics. The antibiotics segment includes cloxacillin, ceftazidime, cefazoline, daptomycin, vancomycin, teicoplanin, and echinocandin. This segment dominates the market share due to its critical role in treating infections once they occur. The adoption of antibiotics is also fuelled by their targeted action against specific pathogens and the ability of certain antibiotics like daptomycin and vancomycin to treat resistant strains of bacteria commonly involved in catheter-related bloodstream infections.

Catheter Related Bloodstream Infections Market Analysis by Region

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is a major market for catheter related bloodstream infections due to the increased use of central venous catheters in critical care settings and the presence of an advanced healthcare infrastructure. The stringent regulatory guidelines set by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) prompt healthcare providers to adopt effective infection control measures and technologies. Thus, the regulatory framework in the United States contributes to the significant market share of catheter related bloodstream infection prevention products and treatments.

Leading Players in the Catheter Related Bloodstream Infections Market

The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Baxter International

Headquartered in Deerfield (Illinois), Baxter International, an American multinational healthcare company is one of the leading players in the market. Baxter is known for its high-quality products that help reduce the risk of CRBSIs, including advanced intravenous solutions.

Aurobindo Pharma Limited

Indian multinational pharmaceutical manufacturing company Aurobindo Pharma Limited commercializes a broad range of medications, including antibiotics for managing catheter related bloodstream infections. The company manufactures antibiotics, such as ceftazidime and vancomycin, which are widely used to treat bloodstream infections.

Eli Lilly and Company

American pharmaceutical company Eli Lilly and Company leverages its extensive R&D capabilities to develop new antibiotics and improve existing ones in order to treat and prevent the resistant strains of bacteria associated with catheter infections.

Other key players in the market include Fresenius SE & Co. KGaA, GSK PLC, Merck & Co., Inc., Mylan N.V. (Viatris), Pfizer Inc., and Sanofi AG.

Key Questions Answered in the Catheter Related Bloodstream Infections Market Report

• What was the catheter related bloodstream infections market value in 2024?
• What is the catheter related bloodstream infections market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is market segmentation based on drug class?
• What is the market breakup based on the route of administration?
• What is the market breakup by indication?
• Who are the major distribution channels in the market?
• What are the major factors aiding the catheter related bloodstream infections market demand?
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major catheter related bloodstream infections market trends?
• How does the rise in the geriatric population impact the market size?
• Which drug class will dominate the market share?
• Which route of administration is expected to have a high market value in the coming years?
• Which distribution channel will experience the highest demand in the market segment?
• Which indication is projected to contribute to the highest market growth?
• Who are the key players involved in the catheter related bloodstream infections market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.